Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04669002 · ClinicalTrials.gov registry record · Phase 2
EP0057 in Combination With Olaparib in Advanced Ovarian Cancer
A Phase 2 study, sponsored by Ellipses Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT04669002 is a Phase 2 study that has completed, run by Ellipses Pharma. The registered enrollment target is 34 participants.
The verdict
NCT04669002, a Phase 2 study, has completed, sponsored by Ellipses Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
EP0057-201 is a Phase 2A/B adaptive design study. Phase 2A will test EP0057 in combination with Olaparib and Phase 2B, the randomised part of the study, will test EP0057 in combination with Olaparib against SOC chemotherapy. When EP0057 is combined with Olaparib, it is envisaged that the combination should improve therapeutic responses in the recurrent ovarian cancer disease setting. EP0057 is an investigational nanoparticle-drug conjugate administered intravenously. The rationale for developing EP0057 is to enable selective entry of EP0057 into tumour tissue and as a result create preferential accumulation of EP0057, and therefore of the payload Camptothecin, to translate into maximum tumour cell killing.
Interventions
- DRUG EP0057
- DRUG Olaparib tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2020-12-14 |
| Est. Completion | 2023-05-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04669002
The ClinicalTrials.gov registry entry for NCT04669002 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ellipses Pharma, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which EP0057 is the first listed.
NCT04669002 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04669002 about?
NCT04669002 is a clinical study titled "EP0057 in Combination With Olaparib in Advanced Ovarian Cancer". EP0057-201 is a Phase 2A/B adaptive design study. Phase 2A will test EP0057 in combination with Olaparib and Phase 2B, the randomised part of the study, will test EP0057 in combination with Olaparib against SOC chemotherapy. When EP0057 is combined with Olaparib, it is envisaged that the combination...
What is the current status of trial NCT04669002?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2020-12-14. Estimated completion is 2023-05-05.
What interventions are being tested in trial NCT04669002?
The interventions under investigation include: EP0057 (DRUG), Olaparib tablets (DRUG).
Who is sponsoring clinical trial NCT04669002?
This trial is sponsored by Ellipses Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.